This project will develop a molecular signature, based on genomics and metabolomics, obtained from liquid biopsies to predict the response to radiotherapy and early relapse in patients with prostate cancer undergoing external radiotherapy (SBRT and IMRT).
Prostate cancer is the second most common cancer among men with 1.28 million cases diagnosed in 2018 worldwide, 88.4% of which were diagnosed in developed countries. It is the sixth leading cause of cancer-related deaths in men, with higher mortality rates in developing countries, and much higher morbidity levels in developed countries thanks to widespread diagnostic methods and early detection. The results obtained in the project will make it possible to predict the response to therapy, as well as to detect early relapse for this type of cancer.
of cases diagnosed in 2018 worldwide.